Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
SERZONE is an oral tablet small-molecule antidepressant approved by Bristol Myers Squibb in December 1994. The drug's specific mechanism of action and therapeutic indication are not fully detailed in available data, but it represents a legacy psychiatric medication from the 1990s era. As a non-controlled oral agent, it likely targets central nervous system pathways relevant to mood disorders.
Product approaching loss of exclusivity with low current commercial opportunity and likely declining team investment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on SERZONE in 2024 offers minimal career advancement given the product's LOE-approaching status and zero linked job openings. This role would involve managing commercial wind-down, generic transition, and potential portfolio rationalization rather than growth-oriented brand building.
Worked on SERZONE at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.